{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:19:34Z","timestamp":1760548774391,"version":"3.37.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/cad.0b013e3282f3fd2e","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:03:20Z","timestamp":1236258200000},"page":"275-281","source":"Crossref","is-referenced-by-count":23,"title":["Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients"],"prefix":"10.1097","volume":"19","author":[{"given":"Zyting","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ting","family":"Liau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muh-Hwa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin R.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ctrv.2007.04.006","article-title":"Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials","volume":"33","author":"Estevez","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2005.06.010","article-title":"Taxanes as first-line treatment for advanced non-small cell lung cancer: a systematic review and practice guideline","volume":"50","author":"Chu","year":"2005","journal-title":"Lung Cancer"},{"issue":"Suppl 6","key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin Oncol"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0921-4410(03)21003-6","article-title":"Tubulin-targeting agents","volume":"21","author":"Hait","year":"2003","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1254\/jphs.FP0040603","article-title":"Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4","volume":"97","author":"Taniguchi","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ijc.21013","article-title":"MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid","volume":"116","author":"Huisman","year":"2005","journal-title":"Int J Cancer"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1166\/jnn.2006.440","article-title":"Improved oral delivery of paclitaxel following administration in nanoemulsion formulations","volume":"6","author":"Tiwari","year":"2006","journal-title":"J Nanosci Nanotechnol"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11095-006-0022-2","article-title":"Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules","volume":"23","author":"Peltier","year":"2006","journal-title":"Pharm Res"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2006.02.018","article-title":"Polyethylene glycol\u2013phosphatidylethanolamine conjugate (PEG\u2013PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux","volume":"315","author":"Dabholkar","year":"2006","journal-title":"Int J Pharm"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bjc.6603312","article-title":"A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer","volume":"95","author":"Veltkamp","year":"2006","journal-title":"Br J Cancer"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-006-0245-2","article-title":"A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application","volume":"59","author":"Veltkamp","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF03192303","article-title":"Human liver microsomal metabolism of paclitaxel and drug interactions","volume":"23","author":"Desai","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","article-title":"Cyclosporin A is a broad-spectrum multidrug resistance modulator","volume":"11","author":"Qadir","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"key":"R16-5-20210203","first-page":"3379","article-title":"Coadministration of oral cyclosporin A enables oral therapy with paclitaxel","volume":"5","author":"Meerum Terwogt","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.2000.18.12.2468","article-title":"Phase I and pharmacokinetic study of oral paclitaxel","volume":"18","author":"Malingre","year":"2000","journal-title":"J Clin Oncol"},{"key":"R18-5-20210203","first-page":"3459","article-title":"Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel","volume":"6","author":"Britten","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2002.04.058","article-title":"Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/annonc\/mdg078","article-title":"Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer","volume":"14","author":"Kruijtzer","year":"2003","journal-title":"Ann Oncol"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1054\/bjoc.2001.2118","article-title":"The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients","volume":"85","author":"Malingre","year":"2001","journal-title":"Br J Cancer"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1200\/JCO.2001.19.20.4065","article-title":"Mechanism-based pharmacokinetic model for paclitaxel","volume":"19","author":"Henningsson","year":"2001","journal-title":"J Clin Oncol"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10637-005-5863-8","article-title":"Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial","volume":"23","author":"Chao","year":"2005","journal-title":"Invest New Drugs"},{"key":"R24-5-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00001813-200104000-00008","article-title":"The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel","volume":"12","author":"Malingre","year":"2001","journal-title":"Anticancer Drugs"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/rcm.2577","article-title":"Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography\/tandem mass spectrometry","volume":"20","author":"Gardner","year":"2006","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0026-895X(24)12040-8","article-title":"Measurement of fraction unbound paclitaxel in human plasma","volume":"28","author":"Brouwer","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4161\/cbt.4.5.1664","article-title":"Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of Taxol\u00ae and Paxene\u00ae","volume":"4","author":"Scripture","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-001-0394-2","article-title":"Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut","volume":"49","author":"Bardelmeijer","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4161\/cbt.4.8.1867","article-title":"Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel","volume":"4","author":"Smith","year":"2005","journal-title":"Cancer Biol Ther"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3282f3fd2e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:27:11Z","timestamp":1738978031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200803000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3282f3fd2e","relation":{},"ISSN":["0959-4973"],"issn-type":[{"type":"print","value":"0959-4973"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}